The Chhattisgarh government’s health department is enforcing a strict zero-tolerance policy when it comes to the quality of medicines. In a recent move, M/s. Effi Parenterals has been served with a show-cause notice, potentially leading to the company being blacklisted. The action stems from concerns over the quality of drugs supplied by the firm.
To ensure drug quality, the CGMSCL mandates that all batches of drugs supplied to health institutions undergo rigorous testing at NABL-accredited labs before distribution. This process ensures that only approved medications reach patients.
Specifically, the firm supplied Albendazole Tablets IP 400 mg (Drug Code – D12), specifically batches PGT25451, PGT25450, PGT25480, and PGT25229. These were tested at the State Drug Testing and Research Laboratory in Raipur before distribution. The laboratory found that these batches failed the quality tests. Following these findings, the firm was served with a show-cause notice, signaling a possible blacklisting, due to the zero-tolerance policy on drug quality. Furthermore, the supplier is obligated to retrieve all failed batches from the drug warehouses.
The firm had previously supplied 14 batches of Albendazole Tablets IP 400 mg. These batches were cleared for distribution after passing the NABL tests.